Pharming Group N.V. : Buyers are coming back

01/13/2021 | 08:26am EST

long trade Live

Entry price : 1.193€ | Target : 1.44€ | Stop-loss : 1.084€ | Potential : 20.7%

Shares in Pharming Group N.V. have recently benefitted from a regain of interest by market participants. The technical chart pattern suggests a continuation of the upward movement. Investors have an opportunity to buy the stock and target the € 1.44.

Summary

• The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
• For a short-term investment strategy, the company has poor fundamentals.

Strengths

• The prospective high growth for the next fiscal years is among the main assets of the company
• Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
• Thanks to a sound financial situation, the firm has significant leeway for investment.
• Analysts covering this company mostly recommend stock overweighting or purchase.
• The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

• For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
• For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
• For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart

Subsector Pharmaceuticals - NEC

1st jan. Capitalization (M$) Investor Rating PHARMING GROUP N.V. -6.84% 920 JOHNSON & JOHNSON 3.92% 430 552 ROCHE HOLDING AG 3.06% 308 615 NOVARTIS AG 2.73% 220 726 MERCK & CO., INC. -1.00% 204 882 PFIZER INC. -0.71% 203 159 ABBVIE INC. 3.46% 195 720 ELI LILLY AND COMPANY 22.09% 186 883 NOVO NORDISK A/S 4.18% 168 128 AMGEN INC. 10.26% 147 580 BRISTOL-MYERS SQUIBB COMPAN.. 4.08% 145 890

More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.